The COVID-19 Ontario Pregnancy Event (COPE) Network: Assessing the impact of COVID-19 in pregnancy on maternal, fetal and newborn health [Added supplement: COVID-19 Variant Supplement]
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 172760, 175557
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$625,031.42Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Darine El-Chaar, Marc-Andre LangloisResearch Location
CanadaLead Research Institution
Ottawa Hospital Research Institute Clinical EpidemiologyResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)Newborns (birth to 1 month)
Vulnerable Population
Pregnant womenOther
Occupations of Interest
Unspecified
Abstract
In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2 infection in pregnant women, maternal and neonatal biological samples will be prospectively collected from women with confirmed or suspected COVID-19 at participating hospitals across Ontario. Samples will be tested for the SARS-CoV-2 serology and viral load. The study population will consist of pregnant women with confirmed or suspected COVID-19 at any point during pregnancy, who will be delivering at a participating hospital within Ontario and agree to provide maternal and/or neonatal samples. Outcomes for the study objective will be ascertained through the collection and testing of biological samples from the mother and/or infant. Specifically we will: 1) Assess vaginal mucosa, amniotic fluid, placenta, breastmilk, cord blood and neonatal nasopharyngeal swab for RNA particles of SARS-CoV-2, by ddPCR. 2) Examine the impact of SARS-CoV-2 impact on neonate with respect to serology and viral load, in addition to placenta pathology findings and ddPCR. 3) Assess vertical transmission and the effect of SARS-CoV-2 through placental pathology examina